Kantar, Indonesia Urban Brand Footprint 2020: Top FMCG Brands that have been chosen by Indonesian consumers

FYI: Indomie continues to be number one chosen brand in Indonesia Urban  Brands Ensure Growth Using Key Levers Based on Evolving Consumer Needs JAKARTA, Indonesia, June 18, 2020 /PRNewswire/ -- Kantar Indonesia, Worldpanel Division announces the launch of the 2020 Indonesia Urban Brand Footprint Ranking. Brand Footprint is an annual study by Kantar that measures which brands are the most chosen ones by consumers. Brand Footprint covers FMCG sectors, e.g. food, beverages, home care, dairy, health and beauty products. Indonesia Urban ranking covers 85% of total Urban households and represents 30 million within the urban areas of Indonesia.   Venu Madhav, General Manager of Kantar Indonesia, Worldpanel Division shared that "Opportunities for brands to grow is there; however, brands cannot afford to expect growth to happen organically. Brands will still need to ensure that they remain relevant to the consumer and earn their growth". Key findings of Brand Footprint Indonesia Urban: Local brands manage to establish stronger presence, where 4 of the top 5 brands are coming from local manufacturers. Local players' ability to adopt fast to the latest consumer trends enable them to be more productive in launching new innovations to the local market. Food category dominates the top 10 ranking, whilst top players To keep reading about Kantar, Indonesia Urban Brand Footprint 2020: Top FMCG Brands that have been chosen by Indonesian consumers, Click on the link. Seoul, Korea
http://dlvr.it/RZFrvm

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

Coronavirus Hasn't Diminished Tech Stocks' Allure

Image
FYI: By Caitlin McCabe Caitlin McCabe The Wall Street Journal Biography caitlin.mccabe@wsj.com Updated April 20, 2020 6:14 pm ET The FANG trade hasn’t lost its bite. Big technology stocks are again charging to new heights and propelling the broader stock market, which is swiftly rebounding after a punishing selloff. The NYSE FANG+ index—which comprises Facebook Inc., FB -0.56% Amazon.com Inc., AMZN 0.78% Netflix Inc. NFLX 3.44% and Google parent Alphabet Inc., GOOG -1.30% along with Apple Inc., AAPL -2.08% Twitter Inc., Tesla Inc., TSLA -1.00% Nvidia Corp. NVDA -1.80% and the Chinese behemoths Alibaba Group Holding Ltd. and Baidu Inc. —is up 11% year-to-date after a dramatic rally last week. The four FANG stocks added $251 billion in market value last week, their biggest gain on record dating to Facebook’s 2012 initial public offering. The S&P 500, in comparison, is down 13% in 2020 but has r
Read more

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. SHANGHAI, March 28, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phase 2 trial of HLX10, which will be presented at upcoming medical conferences. Professor Shukui Qin of No.81 Hospital of People's Liberation Army and Professor Jin Li of Shanghai East Hospital affiliated to Shang
Read more